Interaction of Brain-Derived Neurotrophic Factor with the Effects of Chronic Methamphetamine on Prepulse Inhibition in Mice Is Independent of Dopamine D3 Receptors

Overview

Journal Biomedicines

Specialty Biomedical Engineering

Date 2023 Aug 26

PMID 37626786

Authors

Samuel Hogarth

Emily J Jaehne

Xiangjun Xu

Quenten Schwarz

Maarten van den Buuse

Affiliations

Soon will be listed here.

Abstract

The aim of the present study was to gain a better understanding of the role of brain-derived neurotrophic factor (BDNF) and dopamine D3 receptors in the effects of chronic methamphetamine (METH) on prepulse inhibition (PPI), an endophenotype of psychosis. We compared the effect of a three-week adolescent METH treatment protocol on the regulation of PPI in wildtype mice, BDNF heterozygous mice (HET), D3 receptor knockout mice (D3KO), and double-mutant mice (DM) with both BDNF heterozygosity and D3 receptor knockout. Chronic METH induced disruption of PPI regulation in male mice with BDNF haploinsufficiency (HET and DM), independent of D3 receptor knockout. Specifically, these mice showed reduced baseline PPI, as well as attenuated disruption of PPI induced by acute treatment with the dopamine receptor agonist, apomorphine (APO), or the glutamate NMDA receptor antagonist, MK-801. In contrast, there were no effects of BDNF heterozygosity or D3 knockout on PPI regulation in female mice. Chronic METH pretreatment induced the expected locomotor hyperactivity sensitisation, where female HET and DM mice also showed endogenous sensitisation. Differential sex-specific effects of genotype and METH pretreatment were observed on dopamine receptor and dopamine transporter gene expression in the striatum and frontal cortex. Taken together, these results show a significant involvement of BDNF in the long-term effects of METH on PPI, particularly in male mice, but these effects appear independent of D3 receptors. The role of this receptor in psychosis endophenotypes therefore remains unclear.

Citing Articles

The Role of Dopamine in Neurological, Psychiatric, and Metabolic Disorders and Cancer: A Complex Web of Interactions.

Speranza L, Miniaci M, Volpicelli F Biomedicines. 2025; 13(2).

PMID: 40002905 PMC: 11853172. DOI: 10.3390/biomedicines13020492.

References

Moraga-Amaro R, Gonzalez H, Pacheco R, Stehberg J . Dopamine receptor D3 deficiency results in chronic depression and anxiety. Behav Brain Res. 2014; 274:186-93. DOI: 10.1016/j.bbr.2014.07.055. View

Manning E, Halberstadt A, van den Buuse M . BDNF-Deficient Mice Show Reduced Psychosis-Related Behaviors Following Chronic Methamphetamine. Int J Neuropsychopharmacol. 2015; 19(4). PMC: 4851263. DOI: 10.1093/ijnp/pyv116. View

Swerdlow N, Weber M, Qu Y, Light G, Braff D . Realistic expectations of prepulse inhibition in translational models for schizophrenia research. Psychopharmacology (Berl). 2008; 199(3):331-88. PMC: 2771731. DOI: 10.1007/s00213-008-1072-4. View

Bramness J, Gundersen O, Guterstam J, Rognli E, Konstenius M, Loberg E . Amphetamine-induced psychosis--a separate diagnostic entity or primary psychosis triggered in the vulnerable?. BMC Psychiatry. 2012; 12:221. PMC: 3554477. DOI: 10.1186/1471-244X-12-221. View

Kernie S, Liebl D, Parada L . BDNF regulates eating behavior and locomotor activity in mice. EMBO J. 2000; 19(6):1290-300. PMC: 305670. DOI: 10.1093/emboj/19.6.1290. View

Advani T, Koek W, Hensler J . Gender differences in the enhanced vulnerability of BDNF+/- mice to mild stress. Int J Neuropsychopharmacol. 2009; 12(5):583-8. DOI: 10.1017/S1461145709000248. View

McKetin R, Hickey K, Devlin K, Lawrence K . The risk of psychotic symptoms associated with recreational methamphetamine use. Drug Alcohol Rev. 2010; 29(4):358-63. DOI: 10.1111/j.1465-3362.2009.00160.x. View

Joyce J, Renish L, Osredkar T, Walro J, Kucera J, Dluzen D . Methamphetamine-induced loss of striatal dopamine innervation in BDNF heterozygote mice does not further reduce D3 receptor concentrations. Synapse. 2004; 52(1):11-9. DOI: 10.1002/syn.10309. View

Moratalla R, Khairnar A, Simola N, Granado N, Garcia-Montes J, Porceddu P . Amphetamine-related drugs neurotoxicity in humans and in experimental animals: Main mechanisms. Prog Neurobiol. 2015; 155:149-170. DOI: 10.1016/j.pneurobio.2015.09.011. View

10.

Xu M, Koeltzow T, Santiago G, Moratalla R, Cooper D, Hu X . Dopamine D3 receptor mutant mice exhibit increased behavioral sensitivity to concurrent stimulation of D1 and D2 receptors. Neuron. 1997; 19(4):837-48. DOI: 10.1016/s0896-6273(00)80965-4. View

11.

Chan C, Ye K . Sex differences in brain-derived neurotrophic factor signaling and functions. J Neurosci Res. 2016; 95(1-2):328-335. PMC: 5271179. DOI: 10.1002/jnr.23863. View

12.

Swerdlow N, Caine S, Braff D, Geyer M . The neural substrates of sensorimotor gating of the startle reflex: a review of recent findings and their implications. J Psychopharmacol. 2012; 6(2):176-90. DOI: 10.1177/026988119200600210. View

13.

Gururajan A, Hill R, van den Buuse M . Brain-derived neurotrophic factor heterozygous mutant rats show selective cognitive changes and vulnerability to chronic corticosterone treatment. Neuroscience. 2014; 284:297-310. DOI: 10.1016/j.neuroscience.2014.10.009. View

14.

Sokoloff P, Giros B, Martres M, Bouthenet M, Schwartz J . Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics. Nature. 1990; 347(6289):146-51. DOI: 10.1038/347146a0. View

15.

Hashimoto T, Bergen S, Nguyen Q, Xu B, Monteggia L, Pierri J . Relationship of brain-derived neurotrophic factor and its receptor TrkB to altered inhibitory prefrontal circuitry in schizophrenia. J Neurosci. 2005; 25(2):372-83. PMC: 6725470. DOI: 10.1523/JNEUROSCI.4035-04.2005. View

16.

Firth J, Cotter J, Carney R, Yung A . The pro-cognitive mechanisms of physical exercise in people with schizophrenia. Br J Pharmacol. 2017; 174(19):3161-3172. PMC: 5595765. DOI: 10.1111/bph.13772. View

17.

Du X, Hill R . 7,8-Dihydroxyflavone as a pro-neurotrophic treatment for neurodevelopmental disorders. Neurochem Int. 2015; 89:170-80. DOI: 10.1016/j.neuint.2015.07.021. View

18.

Notaras M, van den Buuse M . Brain-Derived Neurotrophic Factor (BDNF): Novel Insights into Regulation and Genetic Variation. Neuroscientist. 2018; 25(5):434-454. DOI: 10.1177/1073858418810142. View

19.

Brisch R, Saniotis A, Wolf R, Bielau H, Bernstein H, Steiner J . The role of dopamine in schizophrenia from a neurobiological and evolutionary perspective: old fashioned, but still in vogue. Front Psychiatry. 2014; 5:47. PMC: 4032934. DOI: 10.3389/fpsyt.2014.00047. View

20.

Pierce R, Kalivas P . A circuitry model of the expression of behavioral sensitization to amphetamine-like psychostimulants. Brain Res Brain Res Rev. 1997; 25(2):192-216. DOI: 10.1016/s0165-0173(97)00021-0. View